Cat.#: ASSD-111
| Description | Propidium iodide (PI) is a widely used red-fluorescent intercalating agent that binds and labels nucleic acids. When bound to the nucleic acids, its fluorescence is enhanced 20- to 30-fold. Frequently used with Oxazole Yellow (YP1) when staining for apoptotic and necrotic cells as apoptotic cells remain impermeant to propidium iodide but permeable to Oxazole Yellow (YP1). |
| Synonyms | PI |
| Size | 10 mg, 50 mg |
| Applications | Flow cytometry, fluorescent microscopy and confocal laser scanning microscopy. Propidium iodide is membrane impermeant and is therefore frequently used to selectively identify dead cells and is commonly used in flow cytometry to evaluate cell viability. |
| Chemical Name | 2,7-Diamino-9-phenyl-10 (diethylaminopropyl)-phenanthridium iodide methiodide |
| Molecule Weight | 668.39 |
| Molecular formula | C27H34I2N4 |
| CAS Number | 25535-16-4 |
| PubChem identifier | 104981 |
| MDL Number | MFCD00011921 |
| Purity | >97% |
| Solubility | Soluble in water (5 mM) |
| Form | Purple solid |
| Excitation | 535 nm |
| Emission | 617 nm |
| Storage | Store at 4° C |
| Shipping | Shipped at 4°C |
| Cat.# | Name | Size | Price |
|---|---|---|---|
| ASSD-208 | NBD-X, succinimidyl ester (AC208) | 100 mg | inquiry |
| ASSD-170 | BAPTA-AM (AC170) | 25 mg | inquiry |
| ASSD-166 | FURA-2 (AC166) | 1 mg | inquiry |
| ASSD-218 | 6-Carboxy-2′,7′-dichlorofluorescein-3′,6′-diacetatesuccinimidyl Ester (AC218) | 25 mg | inquiry |
| ASSD-149 | D-Luciferin sodium salt (AC149) | 10 mg, 50 mg, 100 mg | inquiry |
| ASSD-103 | DAPI Staining Solution (1mg/mL) (AC103) | 1 mL, 5 mL, | inquiry |
| ASSD-132 | Congo Red (AC132) | 100 mg, 1g | inquiry |
| ASSD-118 | BrdU (5-Bromo-2′-deoxyuridine) (AC118) | 200 mg, 100 mg, 1 g, 5g | inquiry |
| ASSD-200 | Ethylenediamine N-[(Cyanine 3) Monofunctional Hexanoic Acid]-N′-[3-difluoromethyl-4-phosphoanilinamidosuccinic Acid] Diamide (AC200) | 500 μg | inquiry |
| ASSD-178 | 5-(Iodoacetamido)fluorescein (AC178) | 25 mg, 100 mg, 250 mg | inquiry |
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.